Arizona
Tucson; Arizona Cancer Center
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
California
La Jolla; UCSD Moores Cancer Center
A clinical study evaluating the efficacy, safety, and tolerability of OncoVEX in subjects with inoperable melanoma.
Los Angeles; Jonsson Comprehensive Cancer Center
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Los Angeles; The Angeles Clinic & Research Institute
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Orange; St. Joseph Hospital
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Florida
Bay Pines; Bay Pines VA Healthcare System
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Gainesville; Gainesville Hematology/ Oncology Associates
Phase II Randomized, Open-Label Study of IMC-1121B With Or Without Dacarbazine In Patients With Metastatic Malignant Melanoma
Illinois
Evanston; Evanston Northwestern Healthcare
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Joliet; Joliet Oncology/Hematology Associates, LTD
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Kentucky
Louisville; University of Louisville
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Louisiana
Baton Rouge; Mary Bird Perkins Cancer Center
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Maine
Scarborough; Maine Center for Cancer Medicine and Blood Disorders
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Massachusetts
Various Cities; Research Center
Malignant Melanoma Study CSTI571BUS255
Minnesota
Minneapolis; University of Minnesota
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Robbinsdale; Hubert H Humphrey Cancer Center
A clinical study evaluating the efficacy, safety, and tolerability of OncoVEX in subjects with inoperable melanoma.
Missouri
Columbia; Ellis Fischels Cancer Center
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Nebraska
Lincoln; Southeast Nebraska Hematology/Oncology
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Omaha; Nebraska Methodist Cancer Center
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
New Hampshire
Lebanon; Dartmouth Hitchcock Medical Center
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
New Jersey
Montclair; Mountainside Hospital
A clinical study evaluating the efficacy, safety, and tolerability of OncoVEX in subjects with inoperable melanoma.
Montclair; Atlantic Health Research
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
New York
New York; Columbia University
A clinical study evaluating the efficacy, safety, and tolerability of OncoVEX in subjects with inoperable melanoma.
North Carolina
Chapel Hill; UNC School of Medicine
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Winston-Salem; Derrick L. Davis Regional Cancer Center
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Oregon
Portland; Providence Cancer Center Clinical Trials
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Pennsylvania
Bethlehem; St. Luke's Cancer Center
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Pittsburgh; Cancer Pavilion
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
South Carolina
Greenville; Cancer Center of the Carolinas
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Greenville; Cancer Center of the Carolinas
TNFerade™ plus Radiation for Metastatic Melanoma
Texas
Dallas; Mary Crowley Medical Research Center
A clinical study evaluating the efficacy, safety, and tolerability of OncoVEX in subjects with inoperable melanoma.
Dallas; Mary Crowley Medical Research Center
TNFerade™ plus Radiation for Metastatic Melanoma
San Antonio; San Antonio Cancer Institute
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Tyler; Tyler Cancer Center
TNFerade™ plus Radiation for Metastatic Melanoma
Tyler; Tyler Cancer Center
A clinical study evaluating the efficacy, safety, and tolerability of OncoVEX in subjects with inoperable melanoma.
Virginia
Abingdon; Cancer Outreach Associates
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Washington
Seattle; Seattle Cancer Care Alliance
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
International
Adelaide, South Australia, Australia; Medical Oncology
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Fremantle, WA, Australia; Fremantle Hospital
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Hobart, Tasmania, Australia; Royal Hobart Hospital
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Lismore, NS, Australia; Lismore Base Hospital, Cancer Care & Haematology Unit
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Redcliffe, Australia; Redcliffe Hospital
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Waratah, Australia; Newcastle Melanoma Unit
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Wollongong, Australia; Clinical Trials
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Wooloongabba, Australia; Princess Alexandra Hospital
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Brussels, Belgium; AZ Sint Augustinus
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Brussels, Belgium; Institut Jules Bordet, Medical Oncology
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Calgary, Alberta, Canada; Tom Baker Cancer Centre
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Edmonton, Alberta, Canada; Cross Cancer Institute
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Halifax, Nova Scotia, Canada; QE II Health Sciences Center
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Montreal, Quebec, Canada; Royal Victoria Hospital
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Sudbury, Ontario, Canada; Northeastern Ontario Regional Cancer Centre
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Weston, Ontario, Canada; Humber River Regional Hospital
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Brasov, Romania; Oncology Department County Hospital Brasov
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Cluj Napoca, Romania; Oncology Institute Prof. Dr. Ion Chiricuta
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Cluj Napoca, Romania; Oncology Institute Prof. Dr. Ion Chiricuta
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Hunedoara, Romania; Clinical County Hospital Alexandru Simionescu Hunedoara
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Iasi, Romania; Center of Medical Oncology
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Sibiu, Romania; Clinical County Hospital Sibiu
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Timisoara, Romania; Oncology- Chemotherapy Clinic
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
